TWiV 803: COVID-19 clinical update #79 with Dr. Daniel Griffin
About this episode
In COVID-19 clinical update #79, Daniel Griffin discusses clinical management guidelines, ER visits and hospitalization among children, infection and vaccine induced seroprevalence in the US, antibodies in Kenyan blood donors, infections after vaccination, anticoagulation for thromboprophylaxis, baracitinib efficacy, long-term symptoms in adults, and sustained symptoms after severe disease.
Become a patron of TWiV!
Links for this episode
- Overlooked shortcomings of observational studies (Op For Inf Dis)
- Guidelines for clinical management (Op For Inf Dis)
- ER visits and hospitalization among children (MMWR)
- Hospitalization of adolescents (MMWR)
- Seroprevalence in the US (JAMA)
- Seroprevalence in Kenya (JAMA)
- Infections after vaccine (medRxiv)
- Israel data dashboard
- Guidelines on anticoagulation for thromboprophylaxis (Blood Adv)
- Baricitinib efficacy (Lancet)
- Long term symptoms, US adults (MMWR)
- Severe disease associated with long term symptoms (medRxiv)
- Letters read on TWiV 803
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology
TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology
TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology
TWiV 1307: My heart breaks for flu
This Week in Virology
TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology